FIG 2.

Comparison of overall survival between mutation carriers and noncarriers. (A) Overall survival between mutation carriers and noncarriers for the entire cohort relative to the first diagnosis of metastatic disease. (B) Overall survival between mutation carriers and noncarriers for the metastatic hormone-sensitive prostate cancer cohort relative to the first diagnosis of metastatic disease. (C) Overall survival between mutation carriers and noncarriers for the metastatic castrate-resistant prostate cancer cohort relative to the first diagnosis of metastatic disease.